CSL · 1 day ago
Senior Manager - Customer Marketing
CSL Seqirus is one of the world's largest influenza vaccine providers, on a mission to lessen the burden of influenza worldwide. The Senior Manager of Customer Marketing will play a crucial role in driving U.S. growth strategy, translating customer insights into targeted marketing strategies, and collaborating with cross-functional teams to enhance customer engagement and impact.
BiotechnologyHealth CareHealth DiagnosticsMedical
Responsibilities
Collaborate with segment leads to develop customer-specific marketing tactics that align with brand and business objectives
Create targeted messaging for field sales teams to provide customers with relevant information year-round, supporting the planning and execution of immunization campaigns
Provide field teams with tools, training, and customized resources that help customers manage their annual immunization campaigns
Lead a team of field sales champions to gather feedback on sales execution and enhance field sales tools
Act as the marketing lead for managing CSLS Seqirus’ e-commerce platform, flu360.com
Develop Group Purchasing Organization (GPO) and Physician Buying Group (PBG) communication plans
Coordinate with policy teams to implement tactics in collaboration with advocacy groups and professional medical associations that impact key customer segments
Qualification
Required
Bachelor's degree in Marketing, Business, Life Sciences, or a related field
5+ years of experience in pharmaceutical marketing, commercial strategy, or customer insights
Experience with key CSL Seqirus customer segments and data driven marketing
Strong understanding of the vaccine commercialization environment
Proven ability to lead cross functional initiatives within a highly regulated industry
Preferred
Sales experience is a plus but not required
Company
CSL
CSL develops innovative biotherapies and influenza vaccines that save lives, and help people with life-threatening medical conditions.
Funding
Current Stage
Public CompanyTotal Funding
$111M2013-12-20Acquired
2004-02-06Post Ipo Equity· $111M
1994-06-03IPO
Recent News
Pharma Letter
2026-01-03
2025-10-29
Company data provided by crunchbase